Document:

EXHIBIT 10.3

 

Director Services Agreement

 

Director
Services Agreement made as of January 1, 2017 by and between Nexeon MedSystems Inc, a Nevada Corporation, (hereinafter
the “Company”) and Michael Neitzel with an address of 6006 Yorkville Court, Dallas, Texas 75248 (hereinafter “Director”).

 

Introduction. The Company is a Nevada
corporation with Bylaws that provide for a Board of Directors to be elected by the holders of a majority of the issued and outstanding
shares of common stock in the Company (“Shares”), whereby said members of the Board of Directors are responsible for
overseeing the Company’s management, their duties and compensation, and elect its officers. The Company wishes the Director
to act as one of its Directors and Director hereby agrees to do so under the terms and conditions of this Agreement.

 

1.             
Services. Director will act as Director of the Company, and as such, will be available on an on call as needed basis
subject to reasonable notice, attend and participate in periodic board meetings (either in person or by telephonic connection),
will advise the Company and its management with respect to its business, and will serve on Board Committees as appointed by the
Board of Directors, assuming the Director agrees that he/she is qualified to serve on such a committee.

 

2.             
Compensation. As Compensation for acting as Director of the Company, the Company will provide Director with the following
compensation:

 

2.1          
Director’s Fees. Starting effective with the date on which the Board of Directors passes a resolution authorizing
the Company to pay its Directors an annual Directors Fee, payable in arrears in quarterly installments at the end of each calendar
quarter during which a Director has served as a Director for the Company.

 

2.2          
Director’s Options. At the end of each three (3) month period that Director serves as a Director of the Company,
the Company will grant to Director an option (each “an Option”) to purchase Twelve Thousand Five Hundred (12,500) shares
of the Company’s restricted Common Stock, at a price equal to One Dollar ($1.00) per share or in the alternative the price
per share (the Strike Price) of the Company’s then current 409a valuation. Once established the Strike Price shall remain
effective for any and all Options granted as a result of being a Director until there is a change in any future 409a valuation.
Such 409a valuations shall not be retroactive for options previously granted to the Director. The term of each Option shall be
for a period of four (4) years from the date of issue of each Option.

 

(a)           
Cashless Procedure for Exercise of an Option. Director may exercise some or all of any Option using the following
“Cashless” procedure. At the time of any such exercise, Director may request the Company to apply, as an offset to
the purchase price (the “Offset”) an amount equal to (a) a number of Shares designated by Director (the “Designated
Share Number”) multiplied by the sum equal to a twenty five percent (25%) discount from the closing price per Share represented
by the last trade of the Company’s common shares on a recognized securities exchange in which a minimum of ten thousand (10,000)
Shares shall have been traded on the day the Director exercises the Option, provided that the Director shall not have made any
such day. In such event the number of shares to be issued to Director will be reduced by the Designated Share Number.

 

 

    	1

    	 

    

 

2.3          
Expenses. The Company will reimburse Director for all reasonable out of pocket expenses incurred by Director in acting
as Director, subject to Director providing reasonable documentation and subject to the Company’s policies regarding such
expenses, provided further that it is anticipated that such expenses shall primarily consist of travel expenses to Board Meetings,
or such other expenses discussed and approved by the Company’s CEO and/or Board of Directors.

 

3.             
Disclosure of Information, Assignment of Intellectual Property, and Restrictive Covenant:

 

3.1          
Acknowledgment. Director acknowledges that the Company is in the business of developing, producing, and selling advanced
medical devices; that the Company has developed an excellent reputation and extensive "know-how" and trade secrets relating
to its business and its customers, some of which Director will learn while associated with the Company; and that, the Company has
spent substantial amounts of effort and money to accumulate this know-how and trade secrets and develop its reputation and its
relationship with its clients.

 

3.2          
 Confidential Information. Director recognizes and acknowledges that the Company’s Confidential Information
includes information or trade secrets relating to the properties, composition or structure of the Company’s products or proposed
products or the development, formulation or processing thereof or hardware, information technology, and software, or the Company’s
business, including, without limitation, any and all patents, patents-pending, patent applications, copyrights, trademarks, service
marks, patentable processes and/or products in development, or any other intellectual property, all trade secrets and proprietary
information concerning the Company’s business and affairs, product specifications, data, know-how, formula, compositions,
processes, designs, sketches, photographs, graphs, drawings, samples, inventions and ideas, past, current and planned research
and development, customer or supplier lists, current and anticipated customer requirements, price lists, market studies, business
plans, computer software and programs and database technologies, systems, structures and architectures and related processes, formula,
compositions, improvements, devices, know-how, discoveries, concepts, ideas, designs, method, algorithms, names and expertise of
the Company’s employees and consultants, inventions (whether patentable or not), schematics and other technical, business,
financial, customer and product development plans, forecasts, strategies and information, whether or not marked “confidential.
Additionally, Director recognizes that in the course of Director’s duties, Director will have access to similar information
of the Company’s customers, suppliers or other entities which the Company is required by contract or professional business
practices to keep confidential, and which shall also be deemed as Confidential Information, which Director agrees to treat as such.
Director will not, during or after the term of this agreement, in whole or in part, disclose any Confidential Information to any
person, firm corporation, association or other entity for any reason or purpose whatsoever, nor shall Director make use of such
information and property for his own purposes or for the benefit of any other person, firm, corporation, association or any other
entity (except for the Company) under any circumstances during or after the term of this Agreement.

 

3.3          
Assignment of Intellectual Property. Director agrees to assign and hereby assigns to the Company (the “Assignment”)
any and all rights, improvements, and copyrightable or patentable subject matter and other intellectual property relating to the
Company business, which Director conceives or develops, either alone or with others, or which otherwise arise during the term of
Director providing management services to the Company and for a period of six (6) months thereafter (“Assignable Property”).

 

    	2

    	 

    

 

 

3.4          
Additional Cooperation. Director agrees not to assert any rights against the Company or seek compensation from the
Company for the foregoing assignment or the Company’s use of Assignable Technology. Director will promptly disclose to the
Company all knowledge that Director obtains regarding Assignable Property, and at the request of the Company, and without expense
or additional compensation, Director will provide the Company with whatever assistance, including (i) signing whatever documents
as are requested by the Company to further evidence and perfect the Assignment and obtain for the Company patents, copyright protection,
assignment of rights and protection of trade secrets, or (ii) taking any other action the Company deems appropriate for securing
or protecting its rights in Assignable Property or other intellectual property of the Company.

 

3.5          
Company Property. Director recognizes that all materials that are or which may come into Director's possession during
the time Director acts as a Director to the Company relating to the nature, operation, or activities of the Company remain the
Company's property. Such materials may consist of agreements, invoices, memorandum, books, forms, reference materials, computer
programs, trade secrets, copyrights, trademarks, specifications, designs, programming, promotional material, advertising material,
selling material, financial material, address books, lists, rolodex’s, notes, information pertaining to negotiations, pricing
procedures, technical data and the like. All such materials are the Company's property and Director will not copy or make extracts
of any such materials and will promptly return all such materials to the Company upon demand or, regardless of whether such demand
is made, after the termination of Director’s association with the Company.

 

3.6          
Limited Non-Competition. For a period of eighteen (18) months after Director ceases to be a Director of the Company,
Director shall not become, directly or indirectly, an employee of, or provide consulting services for, or have any ownership interest
in, any other business entity that manufactures or sells “Competitive Products”. As used herein, “Competitive
Products” means: (a) any product which the Company develops or acquires the right to sell from time to time during the term
of this Agreement.

 

3.7          
Director acknowledges that the foregoing provision’s restrictions and time limitations are reasonable and properly
required for the adequate protection of the business of the Company and that in the event such restriction or limitation is deemed
to be unreasonable by an arbitration panel or a Court, then Director agrees to submit to the reduction of said restriction and
limitation to such as the Court may deem reasonable.

 

3.8          
It is the desire and intent of the parties that the provisions of this paragraph shall be enforced to the fullest extent
possible under the laws and public policies applied in each jurisdiction which enforcement is sought. Accordingly, if any particular
provision of this Agreement or portion of this paragraph shall be adjudicated to be invalid or unenforceable, then the subject
provision or paragraph shall be deemed amended or deleted here from, and the provision or paragraph adjudicated to be invalid and
unenforceable shall be deemed revised in accordance with any such jurisdiction. Such deletion or revision, however, applies only
with respect to the operation of this Agreement in the particular jurisdiction in which such adjudication is made.

 

    	3

    	 

    

 

 

3.9          
In the event of a breach of, or threatened breach by Director of the provisions set forth in this section 3, the Company
shall be entitled to (i) an injunction restraining Director from violating these covenants and (ii) payment by Director of the
expenses of obtaining and enforcing such relief. Nothing herein shall be construed as prohibiting the Company from pursuing any
other remedies available to it for such breach or threatened breach including recovery of damages from Director whereby such damages
shall be paid promptly, including the cost of collection thereof.

 

4.1       Indemnification.
The Company (“Indemnifying Party”) agrees to defend, indemnify and hold harmless Director and its representatives,
successors and assigns (“Indemnitee”) for a period during the time Director serves the Company and for a period of
Two (2) year from the date the Director cease being a Director of the Company from, against and in respect of any and all loss,
liability and expense resulting from:

 

(a)       All
liabilities of the Company regardless of every kind and nature, resulting from the Company’s obligation of this Agreement
without limitation, known or unknown, contingent or otherwise; and

 

(b)       Any
and all loss, damage or deficiency resulting from any misrepresentation or breach of warranty or non-fulfillment of any obligation
by the Company under this Agreement or from any misrepresentation in or omission from any certificate or other instrument furnished
or to be furnished to Director pursuant to this Agreement; and

 

4.2       Claims.
If any Indemnitee receives notice of any claim or the commencement of any action or proceeding with respect to which the Indemnifying
Party is obligated to provide indemnification pursuant to Section 5.1, the Indemnitee shall promptly give the Indemnifying Party
notice thereof. Such notice shall be a condition precedent to any liability of the Indemnifying Party under the provisions for
indemnification contained in this Agreement and shall describe the claim in reasonable detail and shall indicate the amount (estimated
if necessary) of the loss that has been or may be sustained by the Indemnitee. The Indemnifying Party shall elect to compromise
or defend, at such Indemnifying Party’s own expense and by such Indemnifying Party’s own counsel. If the Indemnifying
Party elects to compromise or defend such asserted liability, it shall within 30 days (or sooner, if the nature of the asserted
liability so requires) notify the Indemnitee of its intent to do so, and the Indemnitee shall cooperate, at the expense of the
Indemnifying Party, in the compromise of, or defense against, any such asserted liability. Notwithstanding the foregoing, neither
the Indemnifying Party nor the Indemnitee may settle or compromise any claim over the objection of the other; provided, however,
that consent to settlement or compromise shall not be unreasonably withheld. In any event, the Indemnitee and the Indemnifying
Party may each participate, at its own expense, in the defense of such asserted liability. The Indemnitee shall make available
to the Indemnifying Party any books, records or other documents within its control that are necessary or appropriate for such defense.

 

4.3       Costs.
If any legal action or other proceeding is brought for the enforcement or interpretation of any of the rights or provisions of
this Agreement, or because of an alleged dispute, breach, default or misrepresentation in connection with any of the provisions
of this Agreement, each party shall pay its own attorneys’ fees.

 

    	4

    	 

    

 

 

5.       Term.
Director’s term of acting as a Director under this Agreement, and the Term of this Agreement, shall be until either (i) Director
resigns as a Director of the Company or (ii) the majority of the members of the Company’s Board of Directors vote to remove
Director as a Director of the Company; (iii) a majority of the shareholders of the Company vote to elect a Board of Directors consisting
of directors other than Director. Upon the termination of this Agreement, §3 & 4 above shall survive.

 

6.       Miscellaneous.
This Agreement is the entire Agreement as to its subject matter and it supersedes all prior discussions and oral agreements. This
Agreement may not be modified orally, but only by a written amendment or agreement signed by both parties. This Agreement shall
be governed by the internal laws of the State of Nevada.

 

In Witness Whereof the parties hereto have signed or caused
to be signed this Agreement as of the date first set forth above.

	 	 	 	 	 
	Nexeon MedSystems Inc	 	Director	 
	 	 	 	 	 
	 	 	 	 	 
	By:  	/s/ Will Rosellini	 	/s/ Michael Neitzel	 
	 	Will Rosellini, CEO	 	Michael Neitzel	 
	 	 	 	 	 	 

 

 

    	5Exhibit

AMENDMENT NO. 1 TO
CREDIT AGREEMENT
This AMENDMENT NO. 1 to CREDIT AGREEMENT, dated as of November 29, 2016 (this “Amendment”) between GREATBATCH LTD., a New York corporation (the “Borrower”), INTEGER HOLDINGS CORPORATION (“Parent”) and MANUFACTURERS AND TRADERS TRUST COMPANY acting in its capacity as Administrative Agent and the Lenders party hereto.
Background
The Borrower, the Parent, the Lenders and the Administrative Agent have entered into that certain Credit Agreement, dated as of October 27, 2015, which was modified pursuant to that certain Consent of Lenders, dated as of February 9, 2016 and that certain Memorandum of Correction, dated as of April 19, 2016 (as so modified, the “Existing Credit Agreement” and the same, as it may be amended, restated, modified and/or supplemented from time to time, the “Credit Agreement”), which provides for certain extensions of credit to the Borrower, subject to certain conditions.  
The Borrower has requested certain amendments to the financial covenants set forth in Article VII (Financial Covenants) of the Credit Agreement and the requisite Lenders parties to the Credit Agreement are willing to amend the Existing Credit Agreement in the manner and subject to the terms set forth below.
In addition, the Borrower has advised the Lenders party hereto that it is looking into a possible sale-lease back transaction and has asked such Lenders to authorize the Administrative Agent to execute an amendment in their names when and if the proposed sale-leaseback transaction is finalized all on the terms set forth in Section 5 below.
NOW THEREFORE, in consideration of the promises and conditions set forth in this Amendment, and intending to be legally bound, the parties hereto hereby agree as follows:
Section 1.Defined Terms.  Terms defined in this Amendment which are capitalized but not defined shall have the meanings given to such terms in the Existing Credit Agreement.  This Amendment amends the Credit Agreement, as in effect on the date hereof.
SECTION 2.    Amendments.  
2.1    Section 7.1 (Interest Coverage Ratio)  of the Existing Credit Agreement is hereby amended and restated in its entirety to read as follows:

Parent and its Subsidiaries, on a Consolidated basis, shall maintain a ratio of Adjusted EBITDA to Interest Expense (each for the four (4) consecutive preceding fiscal quarters) calculated as of the last day of any fiscal quarter, of at least the ratios specified below:
	
			
	Interest Coverage Ratio
	Period

	 
	 

	3.00 to 1.00
	Through and including the third fiscal quarter of 2016.

	2.50 to 1.00
	Fourth fiscal quarter of 2016 through and including the fourth fiscal quarter of 2017.

	2.75 to 1.00
	First fiscal quarter of 2018 through and including the fourth fiscal quarter of 2018.

	3.00 to 1.00
	First fiscal quarter of 2019 and beyond.

2.2    Section 7.2 (Total Net Leverage Ratio) of the Existing Credit Agreement is hereby amended and restated in its entirety to read as follows:
Parent and its Subsidiaries, on a Consolidated basis, shall maintain a Total Net Leverage Ratio of no more than the ratios specified below:

-2-

	
		
	Maximum Total Net 
Leverage Ratio
	Period

	 
	 

	6.50 to 1.00
	Through and including the third fiscal quarter of 2016.

	6.25 to 1.00
	Fourth fiscal quarter of 2016 through and including the fourth fiscal quarter of 2017.

	6.00 to 1.00
	First fiscal quarter of 2018 and second fiscal quarter of 2018.

	5.75 to 1.00
	Third fiscal quarter of 2018.

	5.50 to 1.00
	Fourth fiscal quarter of 2018.

	5.00 to 1.00
	First fiscal quarter of 2019 and second fiscal quarter of 2019.

	4.75 to 1.00
	Third fiscal quarter of 2019.

	4.50 to 1.00
	Fourth fiscal quarter of 2019.

	4.25 to 1.00
	First fiscal quarter of 2020.

	4.00 to 1.00
	Second fiscal quarter of 2020 and thereafter.

This covenant shall be tested quarterly on the last day of each fiscal quarter.
SECTION 3.    REPRESENTATIONS AND WARRANTIES.  In order to induce the Lenders and the Administrative Agent to agree to the amendments set forth in this Amendment, the Borrower makes the following representations and warranties, which shall survive the execution and delivery of this Amendment:
(a)    As of the date hereof, no Default or Event of Default has occurred and is continuing or would exist immediately after giving effect to the amendments contained herein.
(b)    Each of the representations and warranties of the Loan Parties set forth in the Existing Credit Agreement and other Loan Documents is true and correct in all material respects both before and after giving effect to the amendments contemplated hereby as though each such representation and warranty were made at and as of the date hereof, except to the extent that any such representation and warranty specifically refers to an earlier date, in which case it is true and correct in all material respects as of such earlier date.
(c)    No consent or approval of any third party, or any governmental agency or authority, is necessary in connection with the execution, delivery and/or performance 

-3-

of this Amendment or any other instrument, agreement or other document executed and/or delivered in connection herewith and/or the enforceability hereof or thereof.
(d)    The amendments set forth herein do not conflict with the provisions of the Senior Note Documents or any other indenture or credit facility of the Borrower.
(e)    Upon satisfaction of the conditions set forth in Section 4 (Conditions Precedent) below, the Existing Credit Agreement, as amended by this Amendment and each other Loan Document is and will constitute the legal, valid and binding obligation of the applicable Loan Party, enforceable against it in accordance with the terms thereof.
SECTION 4.    CONDITIONS PRECEDENT.
4.1    The amendments to the Existing Credit Agreement set forth in Section 2 above and the authorizations set forth in Section 5 below shall become effective, as of the date first above written, upon satisfaction of the following:
(a)    the execution and delivery of this Amendment by the Borrower and the Administrative Agent upon the authorization of the Required Financial Covenant Lenders; and
(b)    payment of the fee set forth on Annex A hereto to each of the Lenders referenced thereon; and
(c)    receipt by the Administrative Agent of such other documents and information as the Administrative Agent shall reasonably request on or prior to the date that the condition in clause (a) above is satisfied.
		
	SECTION 5.
	AUTHORIZATION OF LENDERS REGARDING POSSIBLE FUTURE AMENDMENT.

5.1    The Company has advised the Lenders party hereto that it is exploring the possibility of entering into a sale-leaseback transaction (together with related transactions, the “Proposed Sale-Leaseback”) and, in connection therewith, wishes for such Lenders to consent to the same and to authorize the Administrative Agent to execute a further amendment to the Credit Agreement (the “Proposed Sale-Leaseback Amendment”) on each such Lender’s behalf.  Each Lender party hereto does so irrevocably consent to the Proposed Sale-Leaseback Amendment and hereby irrevocably authorizes the Administrative Agent, in its capacity under the Credit Agreement as Agent, to execute the same in the name and on behalf of the undersigned Lender subject to the following terms and conditions.

-4-

5.1.1    The property subject to the Proposed Sale-Leaseback (a) shall have an aggregate fair market value not exceeding $135,000,000 and (b) shall be comprised of only real property, fixtures and assets directly related thereto and proceeds (other than proceeds of the Proposed Sale-Leaseback) of the foregoing. 
5.1.2    The Proposed Sale-Leaseback (a) shall be on terms that are arm’s length with the purchaser/lessor and reasonably satisfactory to the Administrative Agent, (b) shall not be entered into if, at the time thereof, there then exists a Default or Event of Default or one would result therefrom, and (c) is not prohibited by the Senior Note Documents or any other material indenture or credit facility that the Borrower or other Loan Parties are then party to.
5.1.3    The sale of property pursuant to the Proposed Sale-Leaseback shall be consummated and the lease entered into on or before June 30, 2017 (as such date may be extended by the Administrative Agent in its sole discretion).
5.1.4    Proceeds of the Proposed Sale and Leaseback  shall be applied to prepay the Loans, first, to outstanding Term B Loans pro rata among such Term B Loans based on the outstanding principal amount of all Term B Loans, and in each case to reduce the applicable remaining payments under Subsection 2.1.7 (Scheduled Repayment of Term B Loans) of the Credit Agreement (in each case, including payments to be made at maturity) pro rata until there are no outstanding Term B Loans; second, to outstanding Term A Loans pro rata among such Term A Loans based on the outstanding principal amount of all Term A Loans, and in each case to reduce the applicable remaining payments under Subsection 2.1.6 (Scheduled Repayment of Term A Loans) of the Credit Agreement (in each case, including payments to be made at maturity) pro rata until there are no outstanding Term A Loans; and third, to RC Loans without a corresponding permanent reduction of the RC Commitment.
5.1.5    The Proposed Sale-Leaseback Amendment shall be on terms and conditions satisfactory to the Administrative Agent and shall receive the approval of Majority Lenders (for the avoidance of doubt, the Lenders providing consent in this Amendment shall be deemed to have approved the Proposed Sale-Leaseback Amendment).
5.1.6    Each Lender party hereto shall receive an amendment fee in connection with the Proposed Sale-Leaseback Amendment equal to the excess, if any, of (a) the amount such Lender would have received if it were a party to the Proposed Sale-Leaseback Amendment and not a party hereto less (b) the amount of the fee it receives in connection with this Amendment.  To the extent that there may be any assignment of a Lender’s Commitment between the date hereof and the date thereof, as it relates to the amount assigned, the assignee shall only be entitled to receive the amount that the assignor would have received had there been no such assignment.

-5-

5.2    Without limiting the foregoing authorizations, the Lenders party hereto acknowledge that the Proposed Sale-Leaseback Amendment may include provisions, among others, (a) allowing the Administrative Agent to release Liens on the property subject to the Proposed Sale and Leaseback, (b) modifying certain negative covenants  to specifically permit the Proposed Sale-Leaseback as an additional exception without using existing exceptions or “baskets” for such purpose, (c) clarifying the definition of Indebtedness to confirm that operating leases do not constitute off-balance sheet liabilities within the meaning of Indebtedness absent certain other characteristics and (d) allowing for other amendments to the Credit Agreement to accommodate the sale provisions and the lease provisions and the transactions related thereto.  
5.3    In furtherance and not in limitation of Section 6.5 of this Amendment, the authorizations and agreements set forth in this Section 5 shall be binding on any assignee of the Loans or Commitments of the undersigned Lenders.
SECTION 6.    MISCELLANEOUS.
6.1    Counterparts.  This Amendment may be executed in counterparts and by different parties hereto in separate counterparts, each of which, when executed and delivered, shall be deemed to be an original and all of which, when taken together, shall constitute one and the same instrument. A photocopied or facsimile signature shall be deemed to be the functional equivalent of a manually executed original for all purposes.
6.2    Ratification.  Except as specifically modified hereby, all of the terms, covenants and conditions of the Existing Credit Agreement and each of the other Loan Documents are ratified, reaffirmed and confirmed and shall continue in full force and effect as therein written.
6.3    Payment of Expenses.  Without limiting other payment obligations of the Borrower set forth in the Loan Documents, the Borrower agrees to pay all reasonable, out-of-pocket costs and expenses incurred by the Administrative Agent in connection with the preparation, execution and delivery of this Amendment and any other documents or instruments which may be delivered in connection herewith, including, without limitation, the reasonable fees and expenses of its counsel, Drinker Biddle & Reath LLP, whether or not this Amendment shall become effective.
6.4    Governing Law.  This Amendment shall be governed by, and construed in accordance with, the Law of the State of New York (excluding the Laws applicable to conflicts or choice of law).
6.5    Binding Effect.  This Amendment shall be binding upon and inure to the benefit of Borrower, the Administrative Agent, the Lenders and their respective successors 

-6-

and assigns; provided, however, that Borrower may not assign this Amendment or the Existing Credit Agreement or any of its rights hereunder or thereunder without the prior written consent of the Administrative Agent and each Lender and any such prohibited assignment shall be null and void.
6.6    Severability.  If any provision of this Amendment or the application thereof to any Person or circumstance shall be invalid or unenforceable to any extent, the remainder of this Amendment and the application of such provision to any other Person or circumstance shall not be affected thereby and shall be enforced to the greatest extent permitted by law
6.7    References.  From and after the effective date of this Amendment, each reference in the Credit Agreement to “this Agreement”, “hereof”, “hereunder” or words of like import, and all references to the Credit Agreement in any and all Loan Documents, other agreements, instruments, documents, certificates and writings of every kind and nature, shall be deemed to mean the Existing Credit Agreement as modified and amended by this Amendment and as the same may be further amended, modified or supplemented in accordance with the terms thereof.
[signature page follows]

-7-

IN WITNESS WHEREOF, the undersigned have caused this Amendment No. 1 to Credit Agreement to be duly executed by their respective, duly authorized officers as of the date first above written.
BORROWER:

	
		
	GREATBATCH LTD.

	 
	 

	By:
	/s/ Thomas J. Mazza

	Name:
	Thomas J. Mazza

	Title:
	Vice President and Corporate Controller

ADMINISTRATIVE AGENT:

	
		
	MANUFACTURERS AND TRADERS TRUST COMPANY, in its capacity as the Administrative Agent

	 
	 

	By:
	/s/ Michael J. Prendergast

	Name:
	Michael J. Prendergast

	Title:
	Vice President

	
		
	MANUFACTURERS AND TRADERS TRUST COMPANY

	Name of Lender

	 
	 

	 
	 

	By:
	/s/ Michael J. Prendergast

	Name:
	Michael J. Prendergast

	Title:
	Vice President

    

	
		
	CITIZENS BANK, N.A.

	Name of Lender

	 
	 

	By:
	/s/ Jason D. Houseman

	Name:
	Jason D. Houseman

	Title:
	Vice President

    

	
		
	EVANS BANK, N.A.

	Name of Lender

	 
	 

	By:
	/s/ Stephen Bojdak

	Name:
	Stephan Bojdak

	Title:
	VP – Commercial Banking

    

	
		
	FRANKLIN SYNERGY BANK

	Name of Lender

	 
	 

	By:
	/s/ Lisa Fletcher

	Name:
	Lisa Fletcher

	Title:
	Senior Vice President

    

	
		
	CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH

	Name of Lender

	 
	 

	By:
	/s/ Christopher Day

	Name:
	Christopher Day

	Title:
	Authorized Signatory

	 
	 

	By:
	/s/ Karim Rahimtoola

	Name:
	Karim Rahimtoola

	Title:
	Authorized Signatory

    

	
		
	KEYBANK NATIONAL ASSOCIATION

	Name of Lender

	 
	 

	By:
	/s/ Matthew D. Dunson

	Name:
	Matthew D. Dunson

	Title:
	Vice President

    

	
		
	BANK LEUMI USA

	Name of Lender
	 

	 
	 

	By:
	/s/ Douglas J. Meyer

	Name:
	Douglas J. Meyer

	Title:
	Senior Vice President

	 
	 

	By:
	/s/ James A. D’Amato

	Name:
	James A. D’Amato

	Title:
	Vice President

    

	
		
	SIEMENS FINANCIAL SERVICES, INC.

	Name of Lender

	 
	 

	By:
	/s/ Maria Levy

	Name:
	Maria Levy

	Title:
	Vice President

	 
	 

	By:
	/s/ Michael L. Zion

	Name:
	Michael L. Zion

	Title:
	Vice President

    

	
		
	SUMITOMO BANKING CORPORATIONGROUP 

	Name of Lender

	 
	 

	By:
	/s/ Ken Takahaski

	Name:
	Ken Takahashi

	Title:
	Managing Director

    

	
		
	FIFTH THIRD BANK

	Name of Lender

	 
	 

	By:
	/s/ Joshua N. Livingston

	Name:
	Joshua N. Livingston

	Title:
	Duly Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}]]